UVEAL MELANOMA: IMMUNOLOGIC STUDIES

葡萄膜恶性黑色素瘤的生物学是复杂的。 最近发生的冲突 文献表明标准的眼球摘除技术可以 实际上是在传播肿瘤细胞或减少病人的 免疫活性，导致转移性疾病。 因此，一些 作者甚至建议不要摘除葡萄膜炎患者 恶性黑素瘤 在另一个极端，一些作者认为， 眼球摘除术的每一个眼睛与葡萄膜黑色素瘤，即使没有 可检测的增长。 这项提案将着眼于各种免疫学 葡萄膜恶性黑色素瘤患者的参数 威尔斯眼科医院肿瘤科。 待研究的参数 包括：细胞质黑素瘤肿瘤相关抗体（TAA 抗原，以评估TAA水平的预后意义。 将通过白细胞进行细胞介导的免疫活性检测 使用黑素瘤提取物的粘附抑制测定，淋巴母细胞 用各种植物凝集素转化和直接白细胞迁移 在黑色素瘤提取物存在下的抑制。 T淋巴细胞亚群将 通过玫瑰花结形成和市售单克隆抗体进行检查 抗体的 将在新鲜肿瘤组织中检查炎性细胞 使用单克隆抗体和组织化学技术。 患者 葡萄膜黑色素瘤将有他们的组织相容性-HLA型检查，看看 如果这些患者中某些HLA类型的发生率增加， 发生转移的患者相比， 没有肿瘤 最后，从当时的眼液和肿瘤组织中 将检查是否存在肿瘤血管生成 因子使用体内和体外技术。 这些技术将 评估以找到检测这些患者的预后测试， 发展成转移瘤

The biology of uveal malignant melanoma is complex. Recent conflicts in the literature have suggested that the standard enucleation technique may actually be disseminating tumor cells or reducing the patient's immunocompetence, causing metastatic disease. Because of this, some authors have gone so far as to suggest not enucleating a patient with uveal malignant melanoma. At the other extreme, some authors suggest the enucleation of every eye with a uveal melanoma, even if there is no detectable growth. This proposal will look at various immunological parameters in patients with uveal malignant melanoma presenting to the Wills Eye Hospital Oncology Service. The parameters to be studied include: tumor-associated antibodies (TAA) to cytoplasmic melanoma antigens in order to evaluate the prognostic significance of TAA levels. Cell-mediated immunocompetence testing will be performed by leukocyte adherence inhibition assay using melanoma extracts, lymphoblast transformation with various plant lectins, and direct leukocyte migration inhibition in the presence of melanoma extracts. T-lymphocyte subsets will be examined by rosette formation and commercially available monoclonal antibodies. Inflammatory cells will be examined in fresh tumor tissue using monoclonal antibodies and histo-chemical techniques. Patients with uveal melanoma will have their histo-compatability-HLA type examined to see if there are increased incidences of certain HLA types in those patients who develop metastases when compared to those patients who remain tumor-free. Finally, ocular fluids and tumor tissue obtained at the time of enucleation, will be examined for the presence of tumor angiogenesis factor using in vivo and in vitro techniques. These techniques will be evaluated to find prognostic tests for detecting these patients who will go on to develop metastases.